(Q54386002)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10498663%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

title

Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10498663%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10498663%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

author name string

Schiff ER

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10498663%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

Mitchell M

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10498663%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

Casey DE Jr

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10498663%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

Gitlin N

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10498663%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

Lissoos T

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10498663%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

Gelb LD

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10498663%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

Condreay L

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10498663%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

Crowther L

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10498663%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

Rubin M

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10498663%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

Brown N

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10498663%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

language of work or name

English

0 references

publication date

1 October 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10498663%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10498663%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10498663%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10498663%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

page(s)

1082-1087

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10498663%20AND%20SRC:MED&resulttype=core&format=json

Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues

31 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300427

7 January 2021

A preliminary trial of lamivudine for chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300427

7 January 2021

Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300427

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300427

7 January 2021

The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300427

7 January 2021

High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300427

7 January 2021

Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300427

7 January 2021

Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300427

7 January 2021

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300427

7 January 2021

High-capacity in vitro assessment of anti-hepatitis B virus compound selectivity by a virion-specific polymerase chain reaction assay

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300427

7 January 2021

Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300427

7 January 2021

Hepatitis B reactivation after lamivudine

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300427

7 January 2021

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300427

7 January 2021

Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300427

7 January 2021

Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300427

7 January 2021

Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300427

7 January 2021

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300427

7 January 2021

Incidence and clinical significance of e antigen and antibody in acute and chronic liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300427

7 January 2021

Dane particle-associated DNA polymerase and e antigen: relation to chronic hepatitis among carriers of hepatitis B surface antigen

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300427

7 January 2021

Seroconversion from Hepatitis B e Antigen to Antibody in Chronic Type B Hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300427

7 January 2021

Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300427

7 January 2021

Changes in serum hepatitis B virus (HBV) DNA positivity in chronic HBV infection: results of a long-term follow-up study of 138 patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300427

7 January 2021

Antiviral treatment of chronic hepatitis B virus infection: improvement in liver disease with interferon and adenine arabinoside

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300427

7 January 2021

Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300427

7 January 2021

Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300427

7 January 2021

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300427

7 January 2021

Histologic changes in Chinese patients with chronic hepatitis B virus infection after interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300427

7 January 2021